1-4 of 4
Jason McCoy, MS
Close
Sort by
Journal Articles

High Incidence of Thrombotic Events Observed in Patients Receiving Lenalidomide (L) + Dexamethasone (D) (LD) as First-Line Therapy for Multiple Myeloma (MM) without Aspirin (ASA) Prophylaxis.

Jeffrey A. Zonder, MD, Brian G.M. Durie, MD, Jason McCoy, MS, John Crowley, PhD, Jerome B. Zeldis, MD, Ph.D, Lena Ghannam, Bart Barlogie, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 3455.
https://doi.org/10.1182/blood.V106.11.3455.3455
Published: 2005
Journal Articles

SWOG 0204; Phase 2 Trial of Thalidomide (T) + Dexamethasone (D) Induction Followed by Tandem Autotransplant (TAT) and Prednisone (P) + T Maintenance for Multiple Myeloma (MM).

Mohamad A. Hussein, MD, Jason McCoy, MS, Andrzej Jakubowiak, MD, PhD, Brian G. Durie, MD, John J. Crowley, MD, Bart Barlogie, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 1169.
https://doi.org/10.1182/blood.V106.11.1169.1169
Published: 2005
Journal Articles

Extreme Regression: A Statistical Technique for Finding Good or Poor Prognostic Groups, Illustrated Using Myeloma Patient Data from Intergroup Trial S9321.

John J. Crowley, PhD, Jason McCoy, MS, Michael LeBlanc, PhD, Bart Barlogie, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 5202.
https://doi.org/10.1182/blood.V104.11.5202.5202
Published: 2004
Journal Articles

Osteonecrosis of the Jaws in Myeloma: Time Dependent Correlation with Aredia® and Zometa® Use.

Brian G.M. Durie, MD, Michael Katz, Jason McCoy, MS, John Crowley, PhD
Journal: Blood
Blood (2004) 104 (11): 756.
https://doi.org/10.1182/blood.V104.11.756.756
Published: 2004